

Unaudited Financial Results for the Quarter and Half year ended 30th September, 2010

[₹ in Lacs]

[₹ in Lacs]

CONSOLIDATED RESULTS					Particulars	JUBILANT LIFE SCIENCES LIMITED				
Quarter Ended September 30 (Unaudited)		Half Year Ended September 30 (Unaudited)		Year Ended March 31 (Audited)		Quarter Ended September 30 (Unaudited)		Half Year Ended September 30 (Unaudited)		Year Ended March 31 (Audited)
2010	2009	2010	2009	2010		2010	2009	2010	2009	2010
98758	93311	196909	182947	378127	Net sales/Income from operations	66904	62736	135175	123330	244620
452	353	811	850	1740	Other Operating Income	362	237	653	628	1414
99210	93664	197720	183797	379867	Total income	67266	62973	135828	123958	246034
88312	78024	175752	154655	311726	Total expenditure	56001	48804	113140	95783	189009
1791	342	510	1226	(2038)	a) (Increase)/Decrease in stock in trade and work in progress	1021	537	817	1607	(1646)
4474	4511	10266	8679	20185	b) Purchase of traded goods	5530	4444	10556	8021	17531
34474	31922	71007	62733	129043	c) Raw & process materials consumed	27958	26160	58425	51454	105344
5789	5434	12155	10958	23716	d) Stores, spares, chemicals, catalyst & packing material consumed	2741	2672	5944	5312	11608
5469	5780	11001	10528	22003	e) Power & fuel	4930	5305	9974	9597	19946
2045	1796	3780	3301	7327	f) Other manufacturing expenses	1584	1389	2902	2466	5328
19240	18846	37801	37168	74526	g) Staff cost	5157	4321	9711	8522	17600
5048	3079	10003	6159	12468	h) Depreciation	2569	1629	5048	3185	6510
9982	6314	19229	13903	24496	i) Other Expenditure (Selling, general & admin. expenses-Including exchange loss/gain)	4511	2347	9763	5619	6788
10898	15640	21968	29142	68141	Operating profit before Other Income & Interest	11265	14169	22688	28175	57025
424	447	671	797	1986	Other Income	49	284	130	468	1154
11322	16087	22639	29939	70127	Profit before Interest & Exceptional Items	11314	14453	22818	28643	58179
2486	3632	4464	7701	15052	Interest (Net)	863	2557	1445	5479	9971
8836	12455	18175	22238	55075	Profit after Interest but before Exceptional Items	10451	11896	21373	23164	48208
65	4277	2145	(627)	3286	Exceptional items	(710)	3740	491	(1635)	2281
8771	8178	16030	22865	51789	Profit from Ordinary Activities before tax	11161	8156	20882	24799	45927
614	2396	1707	4630	9594	Tax Expenses (Net)	1376	2607	3078	4747	9617
8157	5782	14323	18235	42195	Net profit from Ordinary Activities after tax	9785	5549	17804	20052	36310
-	-	-	-	-	Extraordinary Items (net of tax expenses)	-	-	-	-	-
(52)	14	(159)	(115)	49	Minority Interest	-	-	-	-	-
8209	5768	14482	18350	42146	Net profit after Minority Interest	9785	5549	17804	20052	36310
1588	1475	1588	1475	1588	Paid-up share capital (Face value per share ₹ 1)	1588	1475	1588	1475	1588
				218546	Reserves (excluding revaluation reserve) Earnings per share before and after extraordinary items (Not annualized)					215697
5.17	3.91	9.12	12.44	28.56	Basic (₹)	6.16	3.76	11.21	13.59	24.60
4.71	3.38	8.31	10.74	24.66	Diluted (₹)	5.62	3.24	10.22	11.73	21.24
					Public shareholding					
83627751	72565234	83627751	72565234	83627751	- Number of shares (₹ 1 each)	83627751	72565234	83627751	72565234	83627751
52.67	49.19	52.67	49.19	52.67	- Percentage of shareholding	52.67	49.19	52.67	49.19	52.67
					Promoters and promoter group Shareholding					
					a) Pledged/Encumbered					
8928300	16605000	8928300	16605000	14245000	- Number of shares	8928300	16605000	8928300	16605000	14245000
11.88	22.15	11.88	22.15	18.95	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	11.88	22.15	11.88	22.15	18.95
5.62	11.25	5.62	11.25	8.97	- Percentage of shares (as a % of the total share capital of the company)	5.62	11.25	5.62	11.25	8.97
					b) Non-Encumbered					
66223724	58372024	66223724	58372024	60907024	- Number of shares	66223724	58372024	66223724	58372024	60907024
88.12	77.85	88.12	77.85	81.05	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	88.12	77.85	88.12	77.85	81.05
41.71	39.56	41.71	39.56	38.36	- Percentage of shares (as a % of the total share capital of the company)	41.71	39.56	41.71	39.56	38.36

Notes:

- With effect from 1st October, 2010, the name of the Company has been changed to Jubilant Life Sciences Ltd. from Jubilant Organosys Ltd., to reflect the evolution of the Company into an integrated Pharma & Life Sciences entity.
- The Board has approved a Scheme of Amalgamation and Demerger (Scheme) at its meeting held on 8th July, 2010. Under the Scheme, Speciality Molecules Limited (SML) a wholly owned subsidiary of the Company and Pace Marketing Specialities Limited (PMSL) an exclusive contract manufacturer of adhesives for Consumer Product Division of the Company will merge with the Company as on 31st March 2010. The Agri and Performance Polymer Business of the company (along with PMSL) will be demerged into Jubilant Industries Limited (JIL) on 1st April 2010. On amalgamation, shareholders of PMSL will be issued 5,01,364 equity shares of the Company as consideration for amalgamation and the equity share capital of SML will be cancelled as the same is held wholly by the company. On demerger, shareholders of the company will get one equity share of ₹ 10 each in Jubilant Industries Limited for every twenty equity shares of ₹ 1 each held in the company. The equity shares of JIL will be listed on BSE and NSE. The said scheme has been allowed by the Hon'ble Allahabad High Court on 28th October, 2010 and the same will be effective on completion of certain regulatory requirements. The above results are without giving effect of the same scheme.
- Depreciation for the period is not comparable with the corresponding period of previous year, as previous year numbers are net of reversal of cumulative depreciation necessitated due to change in the depreciation policy amounting to ₹ 779 Lacs (consolidated ₹ 1651 Lacs) for Q2-FY 2010 and ₹ 1558 Lacs (consolidated ₹ 3302 Lacs) for H1-FY 2010.

Segment wise Revenue, Results & Capital Employed (under Clause 41 of the Listing Agreement)										
CONSOLIDATED RESULTS					Particulars	JUBILANT LIFE SCIENCES LIMITED				
Quarter Ended September 30 (Unaudited)		Half Year Ended September 30 (Unaudited)		Year Ended March 31 (Audited)		Quarter Ended September 30 (Unaudited)		Half Year Ended September 30 (Unaudited)		Year Ended March 31 (Audited)
2010	2009	2010	2009	2010		2010	2009	2010	2009	2010
85085	82814	166448	160824	336630	Segment revenue	53166	52225	104706	101271	203266
13746	10638	30634	22356	41951	a. Pharmaceuticals and Life Sciences Products & Services	13811	10652	30642	22292	41808
98831	93452	197082	183180	378581	b. Agri & Performance Polymers	66977	62877	135348	123563	245074
73	141	173	233	454	Total	73	141	173	233	454
98758	93311	196909	182947	378127	Less : Inter segment revenue	66904	62736	135175	123330	244620
85012	82673	166275	160591	336176	Net sales/Income from operations	66904	62736	135175	123330	244620
13746	10638	30634	22356	41951	a. Pharmaceuticals and Life Sciences Products & Services	53093	52084	104533	101038	202812
98758	93311	196909	182947	378127	b. Agri & Performance Polymers	13811	10652	30642	22292	41808
					Total	66904	62736	135175	123330	244620
11623	17497	22371	33468	75130	Segment results (profit+/-/loss-/-) before tax and interest from each segment	11568	15852	22482	32172	63172
1595	(314)	3529	12	1899	a. Pharmaceuticals and Life Sciences Products & Services	1619	(302)	3575	12	1908
13218	17183	25900	33480	77029	b. Agri & Performance Polymers	13187	15550	26057	32184	65080
2486	3632	4464	7701	15052	Total	13187	15550	26057	32184	65080
1976	3394	5502	8594	12250	Less : i. Interest	863	2557	1445	5479	9971
(15)	1979	(96)	(5680)	(2062)	ii. Other un-allocable expenditure (including exceptional items)	1212	3024	3860	7317	11244
					iii. Un-allocable Income (including exceptional items)	(49)	1813	(130)	(5411)	(2062)
8771	8178	16030	22865	51789	Total profit before tax	11161	8156	20882	24799	45927
					Capital Employed (Segment assets less Segment liabilities)					
494015	478147	494015	478147	469012	a. Pharmaceuticals and Life Sciences Products & Services	203149	184959	203149	184959	178632
25579	18760	25579	18760	21481	b. Agri & Performance Polymers	25400	18461	25400	18461	21344
519594	496907	519594	496907	490493	Total capital employed in segments	228549	203420	228549	203420	199976
25531	48688	25531	48688	68739	Add: Un-allocable corporate assets less liabilities	206077	208747	206077	208747	238448
545125	545595	545125	545595	559232	Total capital employed in the Company	434626	412167	434626	412167	438424

Statement of Assets And Liabilities

[₹ in Lacs]

CONSOLIDATED			Particulars	JUBILANT LIFE SCIENCES LIMITED		
As At September 30 (Unaudited)		As At March 31 (Audited)		As At September 30 (Unaudited)		As At March 31 (Audited)
2010	2009	2010		2010	2009	2010
1588	1476	1588	Share holders Funds	1588	1476	1588
228944	166169	218546	a) Capital	229056	165691	215697
3923	3019	3792	b) Reserves and Surplus	-	-	-
287081	364715	311999	Minority Interest	181296	236457	201227
4621	6448	5273	Loan from Banks, Institutions and FCCB's	-	-	-
20109	14758	19242	Loan from Customers	22703	16191	20498
546266	556585	560440	Deferred Tax Liabilities	434643	419815	439010
446287	431460	432452	TOTAL	184242	167639	173144
2484	27970	22371	Fixed Assets	-	24419	18622
3278	3165	3270	Investments-In Liquid Funds	180226	155800	168298
1141	10990	1208	Investments-Others	17	7648	586
71395	56635	69095	Foreign Currency Monetary Items	43073	28950	42471
63056	51777	51861	Translation Difference Account (FCMITDA)	44513	38787	30730
11622	28557	50367	Current Assets, Loans and Advances	4808	22075	43422
60341	53298	51827	a) Inventories	67514	51783	58434
66937	62554	75352	b) Sundry Debtors	45061	37634	51955
46401	44713	46659	c) Cash and Bank balances	44689	39652	44742
-	-	-	d) Other Current Assets	-	-	-
			e) Loans and Advances	-	-	-
			Less : Current Liabilities and Provisions			
			a) Liabilities			
			b) Provisions			
			Miscellaneous Expenditure (Not Written Off or Adjusted)			
546266	556585	560440	TOTAL	434643	419815	439010

4. Exceptional items include :

- Amortization of Foreign Currency Monetary Item Translation Difference Account ₹ -1174 Lacs (Consolidated ₹ -533 Lacs) for Q2-FY 2011 and ₹ 17 Lacs (Consolidated ₹ 1162 Lacs) for H1-FY 2011.
 - Mark to Market loss in respect of unassigned forward contracts/Interest rate swap outstanding at the period end resulting in loss amounting to ₹ 464 Lacs (Consolidated loss amounting to ₹ 598 Lacs) for Q2-FY 2011 and ₹ 474 Lacs (Consolidated ₹ 983 Lacs) for H1-FY 2011.
- Information on investors complaints for the quarter (Nos.): Opening Balance - Nil, New - 7, Disposals - 7, Closing Balance - Nil.
 - Previous year / periods figures have been regrouped/reclassified wherever necessary.
 - The above un-audited results were subjected to limited review by the auditors of the Company and were approved by the Board of Directors at its meeting held on 11th November, 2010.

For Jubilant Life Sciences Limited
(Formerly Jubilant Organosys Ltd.)

Shyam S Bhartia
Chairman & Managing Director

Place : Noida
Dated : 11th November, 2010

visit us at www.jubl.com